Woodline Partners’s Cymabay Therapeutics CBAY Stock Holding History

Woodline Partners’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-532,002	Closed	-$12.6M	–	665
2023 Q4	$12.6M	Buy	532,002 +121,287	+30%	+$2.16M	0.14%	202
2023 Q3	$6.12M	Buy	410,715 +124,998	+44%	+$1.66M	0.07%	289
2023 Q2	$3.13M	Hold	285,717	–	–	0.04%	368
2023 Q1	$2.49M	Buy	+285,717	New	+$2.29M	0.03%	395

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Woodline Partners's CBAY Position: Q1 2024 in Review

Woodline Partners sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 532,002 shares — an estimated $12.6M sold.

Woodline Partners first reported a position in CBAY in Q1 2023 and held it in 4 quarters. The position peaked at $12.6M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

Woodline Partners reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
Woodline Partners sold 532,002 Cymabay Therapeutics shares in Q1 2024, an estimated $12.6M.
Woodline Partners first reported a position in Cymabay Therapeutics in Q1 2023 and held it in 4 quarters.
Woodline Partners's Cymabay Therapeutics position peaked at $12.6M in Q4 2023.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Woodline Partners's 13F filing for Q1 2024, filed 15 May 2024.